603229 Stock Overview
Engages in the research and development, process development, manufacture, and sale of APIs and pharmaceutical intermediates. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Zhejiang Ausun Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥8.28 |
| 52 Week High | CN¥10.89 |
| 52 Week Low | CN¥5.76 |
| Beta | -0.048 |
| 11 Month Change | -8.41% |
| 3 Month Change | 19.65% |
| 1 Year Change | -22.93% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -47.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| 603229 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 2.3% | 1.0% | -0.9% |
| 1Y | -22.9% | -4.8% | 5.4% |
Return vs Industry: 603229 underperformed the CN Pharmaceuticals industry which returned -4.8% over the past year.
Return vs Market: 603229 underperformed the CN Market which returned 5.4% over the past year.
Price Volatility
| 603229 volatility | |
|---|---|
| 603229 Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 603229 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 603229's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 1,174 | Zhiguo Zheng | www.ausunpharm.com |
Zhejiang Ausun Pharmaceutical Co., Ltd. engages in the research and development, process development, manufacture, and sale of APIs and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indications.
Zhejiang Ausun Pharmaceutical Co., Ltd. Fundamentals Summary
| 603229 fundamental statistics | |
|---|---|
| Market cap | CN¥6.87b |
| Earnings (TTM) | CN¥257.55m |
| Revenue (TTM) | CN¥835.23m |
26.7x
P/E Ratio8.2x
P/S RatioIs 603229 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603229 income statement (TTM) | |
|---|---|
| Revenue | CN¥835.23m |
| Cost of Revenue | CN¥377.58m |
| Gross Profit | CN¥457.65m |
| Other Expenses | CN¥200.10m |
| Earnings | CN¥257.55m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.31 |
| Gross Margin | 54.79% |
| Net Profit Margin | 30.84% |
| Debt/Equity Ratio | 13.1% |
How did 603229 perform over the long term?
See historical performance and comparison